KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) has decided to discontinue development of the company's COVID-19 vaccine candidates, V590 and V591. In phase 1 clinical studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. As a result, the company will record a charge in the fourth quarter of 2020. The charge will not impact non-GAAP results.
Merck said the company continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir).
Copyright RTT News/dpa-AFX
© 2021 AFX News
